From Traders Cafe Zac Mir22 Jun 2021 09:34
“it is always good to see a former small cap hit the mainstream media, and this was the case at sprawling pharma services group Open Orphan (ORPH) to start the week featured alongside its stock market bound spin off, Poolbeg Pharma. With the somewhat cute line of how Poolbeg’s flu treatment is something which is not be sniffed at, we are treated to the story in The Times of how the “Donegal deal maker”, Cathal Friel, called up future CEO Jeremy Skillington for him to head up Poolbeg. Apparently, it was an opportunity which was too good to refuse, a message that may be something for some stock market investors to consider as well.”